These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 18180096)

  • 1. A TIMP-1 splice variant transcript: possible role in regulation of TIMP-1 expression.
    Obro NF; Lademann U; Birkenkamp-Demtroder K; Holten-Andersen L; Brünner N; Offenberg H
    Cancer Lett; 2008 Apr; 262(1):64-70. PubMed ID: 18180096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases.
    Zeng ZS; Cohen AM; Zhang ZF; Stetler-Stevenson W; Guillem JG
    Clin Cancer Res; 1995 Aug; 1(8):899-906. PubMed ID: 9816060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasion front-specific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer.
    Kahlert C; Bandapalli OR; Schirmacher P; Weitz J; Brand K
    Anticancer Res; 2008; 28(3A):1459-65. PubMed ID: 18630499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
    Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
    Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
    Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
    Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of tissue inhibitor of metalloproteinase-1 gene correlates with poor outcomes in colorectal cancer.
    Inagaki D; Oshima T; Yoshihara K; Tamura S; Kanazawa A; Yamada T; Yamamoto N; Sato T; Shiozawa M; Morinaga S; Akaike M; Fujii S; Numata K; Kunisaki C; Rino Y; Tanaka K; Masuda M; Imada T
    Anticancer Res; 2010 Oct; 30(10):4127-30. PubMed ID: 21036730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
    Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low expression of reduced folate carrier-1 and folylpolyglutamate synthase correlates with lack of a deleted in colorectal carcinoma mRNA splice variant in normal-appearing mucosa of colorectal carcinoma patients.
    Wettergren Y; Odin E; Nilsson S; Willen R; Carlsson G; Gustavsson B
    Cancer Detect Prev; 2005; 29(4):348-55. PubMed ID: 16122883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas.
    Suga K; Yamamoto T; Yamada Y; Miyatake S; Nakagawa T; Tanigawa N
    Oncol Rep; 2005 May; 13(5):891-7. PubMed ID: 15809755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays.
    Notterman DA; Alon U; Sierk AJ; Levine AJ
    Cancer Res; 2001 Apr; 61(7):3124-30. PubMed ID: 11306497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel AS160 splice variant that regulates GLUT4 translocation and glucose-uptake in rat muscle cells.
    Baus D; Heermeier K; De Hoop M; Metz-Weidmann C; Gassenhuber J; Dittrich W; Welte S; Tennagels N
    Cell Signal; 2008 Dec; 20(12):2237-46. PubMed ID: 18771725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of Krüppel-like factor 9 in human colorectal cancer.
    Kang L; Lü B; Xu J; Hu H; Lai M
    Pathol Int; 2008 Jun; 58(6):334-8. PubMed ID: 18477211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of carcinoembryonic antigen family member 2 expression is an early event in colorectal tumorigenesis.
    Thompson J; Seitz M; Chastre E; Ditter M; Aldrian C; Gespach C; Zimmermann W
    Cancer Res; 1997 May; 57(9):1776-84. PubMed ID: 9135022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.
    Ishizaki T; Katsumata K; Tsuchida A; Wada T; Mori Y; Hisada M; Kawakita H; Aoki T
    Int J Mol Med; 2006 Feb; 17(2):357-62. PubMed ID: 16391837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
    Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
    Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low expression of ORF4, a dominant negative variant of peroxisome proliferator-activated receptor gamma, in colorectal adenocarcinoma.
    Bouancheau D; Jarry A; Mottier S; Toquet C; Masson D; Mosnier JF; Laboisse CL; Denis MG
    Oncol Rep; 2007 Aug; 18(2):489-95. PubMed ID: 17611675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.
    Safranek J; Pesta M; Holubec L; Kulda V; Dreslerova J; Vrzalova J; Topolcan O; Pesek M; Finek J; Treska V
    Anticancer Res; 2009 Jul; 29(7):2513-7. PubMed ID: 19596921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.